243 filings
Page 8 of 13
S-3
ybxkt25uabqe
4 Feb 22
Shelf registration
4:36pm
8-K
2iovdl0pdrqlxmto21
19 Jan 22
InMed Launches Cannabicitran (CBT), Expanding its Rare Cannabinoid Portfolio for the Health and Wellness Sector
4:09pm
8-K
id3 uc7zifzbni
5 Jan 22
InMed Issues Annual Letter to Shareholders Highlighting Key Accomplishments from 2021 and Providing 2022 Outlook
2:22pm
8-K/A
ecqshy
22 Dec 21
Audited Financial Statements
12:00am
8-K
cz1a1gmtgr5qhz8s2
20 Dec 21
InMed Announces Results of 2021 Annual General Meeting
12:00am
8-K
zvrq5c0zz18
23 Nov 21
Other Events
1:32pm
8-K/A
b9z5d5 bpz9tytrc
16 Nov 21
Regulation FD Disclosure
5:29pm
8-K
q9hc2 tklm
10 Nov 21
InMed Pharmaceuticals Reports First Quarter Fiscal 2022 Financial Results and Provides Business Update
1:08pm
8-K
rfo4p097575unsfi
3 Nov 21
Other Events
2:00pm
DEF 14A
3rq1ms
28 Oct 21
Definitive proxy
3:07pm
DEFA14A
qdrf t0huffpuig
28 Oct 21
Additional proxy soliciting materials
2:54pm
8-K
owvi depamyjhn
28 Oct 21
Other Events
1:29pm
D
h8kh0ul407ee xtdqov
28 Oct 21
$4.31M in equity, sold $4.31M, 54 investors
11:29am
S-8
1tl2vcd3fx4qjnuhsg
18 Oct 21
Registration of securities for employees
3:32pm
8-K
k2a4d vtdyp
13 Oct 21
InMed Pharmaceuticals Completes Acquisition of BayMedica Creating a Market Leader in the Manufacturing of Rare Cannabinoids
5:00pm
8-K
2o8higwo
1 Oct 21
Other Events
4:46pm
8-K
5i4ss dzo
30 Sep 21
Regulation FD Disclosure
1:30pm
8-K
sn8o6j
24 Sep 21
InMed Pharmaceuticals Reports Full Year Fiscal 2021 Financial Results and Provides Business Update
4:07pm